Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Cancer Institute (NCI)
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2500114636 |
ChiCTR2500114636 | N/A |
Not yet recruiting |
Venous Thrombosis|Myocardial Infarction|Ischemic Stroke |
2027-12-31 |
|||
NCT05999851 |
EDIPE | N/A |
Not yet recruiting |
Hypertension|Pregnancy Outcomes|Pre-Eclampsia |
2026-05-01 |
2023-08-22 |
Primary Endpoints|Treatments |
|
ChiCTR1900027080 |
ChiCTR1900027080 | N/A |
Recruiting |
Heart Failure, Systolic|Heart Failure, Chronic|Diabetes Complications|Ventricular Dysfunction, Left|Dyspnea|Heart Failure, Diastolic|GNE Myopathy|Coronary Disease|Hypertension |
2022-12-31 |